With its combined dopamine and norepinephrine reuptake inhibition, as well as TAAR1 agonism, solriamfetol provides a novel mechanism of action for the treatment of depression, possibly offering an effective alternative for patients who do not respond well to traditional antidepressants. This evidence concerns the gene TAAR1 and depressive symptom measurement.